Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy
The study evaluates calderasib combined with pembrolizumab as a first-line treatment for KRAS G12C mutant NSCLC.
Asset / Drug
Drug and asset intelligence for Calderasib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.